Testagen vs Adipotide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Testagen is a tetrapeptide bioregulator (Lys-Glu-Asp-Gly) developed by Professor Vladimir Khavinson, tissue-specific for the testes. It supports Leydig cell function, normalization of testosterone biosynthesis, and spermatogenic activity. Testagen is used in men's health protocols for age-related testosterone decline, male fertility support, and testicular anti-aging.
- Adipotide (FTPP) is a chimeric proapoptotic peptide that selectively targets and destroys blood vessels feeding white adipose tissue. It binds prohibitin on the vasculature of fat tissue, delivering a proapoptotic sequence that induces cell death in fat-specific blood vessels, causing targeted fat tissue regression.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Estimated 2-4 hours
- Admin Route
- SubQ, Oral
- Subcutaneous, Intravenous (research)
- Research
- —
- —
- Typical Dose
- 10 mg per day
- Not established for humans; primate studies used 0.1-1 mg/kg
- Frequency
- Daily for 10–30 days
- Daily for 4 weeks (research protocol)
- Key Benefits
- Supports endogenous testosterone synthesis via Leydig cell normalization
- Promotes spermatogenesis and sperm quality
- Anti-aging effects on testicular tissue
- May attenuate age-related testosterone decline
- Mechanistically distinct from TRT — does not suppress HPG axis
- Useful adjunct to Gonadorelin and Kisspeptin-10 in male hormonal protocols
- Supports male fertility without exogenous hormone replacement
- Targeted reduction of white adipose tissue
- Promotes fat vasculature apoptosis without systemic toxicity
- Demonstrated significant fat loss in primate studies
- Potential for visceral and subcutaneous fat reduction
- Novel non-hormonal mechanism distinct from GLP-1 agonists
- Explored for obesity and metabolic syndrome
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant endocrine disruption reported at standard doses
- Renal toxicity observed in primate studies (transient, dose-dependent)
- Dehydration and electrolyte imbalances in research
- Weight regain upon cessation
- Limited human data; side effect profile largely from animal studies
- Stacks With
- —
- —